Bis-heteroaryl derivatives as modulators of protein aggregation
The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
1. A compound of Formula (IA):
wherein
B is indole, indazole, pyrrolopyridine, benzisoxazole, benzofuran, benzothiophene, quinolone, imidazopyridine, quinolinone, or pyrrolidine, each of which is unsubstituted or substituted with —(R 1 ) m ;
wherein m is 0, 1, or 2; and
each R 1 is independently C 1-4 alkyl (optionally substituted with one or more halo or —OC 1-4 alkyl groups), halo, —OH, or OC 1-4 alkyl;
R 2 is H, C 1-5 alkyl (unsubstituted or substituted with one or more halo substituents), —OC 1-4 alkyl, or —SC 1-4 alkyl, or an aryl, monocyclic cycloalkyl, or —C 1-4 alkyl-(monocyclic cycloalkyl) group, wherein each aryl or cycloalkyl is unsubstituted or substituted with halo, C 1-4 alkyl, or halo-C 1-4 alkyl;
A is a 5-membered heteroaryl ring;
Y is absent or is C 1-4 alkylene; and
where when Y is absent, R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic or bicyclic heterocycloalkyl or
each unsubstituted or substituted with one or more R g substituents; and
when Y is C 1-4 alkylene, R 3 and Y taken together with the nitrogen to which R 3 is attached form a monocyclic or bicyclic heterocycloalkyl ring, which ring is unsubstituted or substituted with C 1-4 alkyl or halo; and R 4 is H or C 1-4 alkyl;
wherein each R g substituent is independently C 1-4 alkyl (unsubstituted or substituted with one or more C 1-4 alkoxy, halo-C 1-4 alkoxy, or halo groups), C 3-7 cycloalkyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, or halo; and
R 5 is H or C 1-4 alkyl;
or a pharmaceutically acceptable salt thereof,
provided that the compound is not:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein one or more of the following limitations applies:
(a1) m is 1 or 2; or
(a2) m is 1 or 2, and R 1 is as defined herein, wherein at least one R 1 is C 1-4 alkyl (substituted with one or two halo groups, or with —OC 1-4 alkyl), C 1-3 alkyl (substituted with —CF 3 ), —OH, or —OC 1-4 alkyl;
(b) R 2 is C 1-5 alkyl substituted with two halo groups, —OC 1-4 alkyl, or —SC 1-4 alkyl, or is monocyclic cycloalkyl substituted with halo, C 1-4 alkyl, or halo-C 1-4 alkyl, or is —C 1-4 alkyl-(monocyclic cycloalkyl), wherein the cycloalkyl is unsubstituted or substituted with halo, C 1-4 alkyl, or halo-C 1-4 alkyl, or is aryl substituted with halo, C 1-4 alkyl, or halo-C 1-4 alkyl; and
(c) when R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl, said heterocycloalkyl is substituted with one or more R g substituents and R g is as defined herein; and at least one R g substituent is C 1-4 alkyl (substituted with one or more C 1-4 alkoxy, halo-C 1-4 alkoxy, or halo groups), C 1-4 alkoxy, halo-C 1-4 alkoxy, or halo.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein B is optionally substituted indole, benzofuran, benzothiophene, indazole, benzisoxazole, imidazopyridine, or pyrrolopyridine.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is unsubstituted or substituted C 1-5 alkyl; or is unsubstituted or substituted C 3-5 alkyl.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is monocyclic cycloalkyl or —C 1-4 alkyl-(monocyclic cycloalkyl), wherein each cycloalkyl is unsubstituted or substituted with halo, C 1-4 alkyl, or halo-C 1-4 alkyl.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is optionally substituted aryl.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is substituted C 1-5 alkyl, or substituted monocyclic cycloalkyl, or substituted —C 1-4 alkyl-(monocyclic cycloalkyl), or substituted phenyl.
8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, thiazole, triazole, oxadiazole, thiadiazole, or tetrazole.
9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is absent and R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic or bicyclic heterocycloalkyl ring, unsubstituted or substituted with one or more R g substituents.
10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 taken together with the nitrogen to which they are attached form azetidine, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, 1,1-dioxo-thiomorpholine, azepine, or diazepine, each unsubstituted or substituted with one or more R g substituents.
11. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 taken together with the nitrogen to which they are attached form piperazine substituted with one, two, or three R g substituents.
12. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with one or more R g substituents, and Y is absent.
13. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is C 1-4 alkylene, and R 3 and Y are taken together with the nitrogen to which R 3 is attached form a monocyclic heterocycloalkyl ring, which ring is unsubstituted or substituted with C 1-4 alkyl or halo; and R 4 is H or C 1-4 alkyl.
14. The compound of claim 1 , which is a compound of Formula (II):
wherein
B′ and B″ together form indole, indazole, pyrrolopyridine, benzisoxazole, benzofuran, benzothiophene, or imidazopyridine; and
R′, R 2 , R 3 , R 4 , R 5 , m, A, and Y are as defined in any one of the preceding claims;
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , which is a compound of Formula (III):
wherein
B′ and B″ together form indole, indazole, pyrrolopyridine, benzisoxazole, benzofuran, benzothiophene, or imidazopyridine; and
R′, R 2 , R 3 , R 4 , R 5 , m, and Y are as defined in any one of the preceding claims;
or a pharmaceutically acceptable salt thereof.
16. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
17. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
18. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
20. A method of treating a neurodegenerative disease or condition associated with protein or peptide aggregation, comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof.
21. A method of interfering with the accumulation of protein or peptide aggregates in a cell, or preventing, slowing, reversing, or inhibiting protein or peptide aggregation in a cell, comprising contacting the cell with an effective amount of at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the contacting is in vitro, ex vivo, or in vivo.